PTC 596

Drug Profile

PTC 596

Alternative Names: PTC596

Latest Information Update: 20 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PTC Therapeutics
  • Developer PTC Therapeutics; University of Oklahoma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action BMI1 protein inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fallopian tube cancer; Glioblastoma; Glioma; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 20 Sep 2018 Phase-I development in Solid tumours (Late-stage disease, Monotherapy, Metastatic disease, Inoperable/Unresectable) is ongoing in USA, Canada (PO) (NCT02404480) (PTC therapeutics pipeline, September 2018)
  • 28 Aug 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy) in Canada (PO)
  • 01 Aug 2018 Phase-I clinical trials in Glioblastoma (In adolescents, In adults, In children, Newly diagnosed) in USA (PO) (NCT03605550)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top